Advertisement
Canada markets closed

  • S&P/TSX

    22,308.93
    -66.90 (-0.30%)
     

  • S&P 500

    5,222.68
    +8.60 (+0.16%)
     

  • DOW

    39,512.84
    +125.08 (+0.32%)
     

  • CAD/USD

    0.7317
    +0.0006 (+0.08%)
     

  • CRUDE OIL

    78.20
    -1.06 (-1.34%)
     

  • Bitcoin CAD

    83,210.02
    -2,816.81 (-3.27%)
     

  • CMC Crypto 200

    1,261.13
    -96.88 (-7.13%)
     

  • GOLD FUTURES

    2,366.90
    +26.60 (+1.14%)
     

  • RUSSELL 2000

    2,059.78
    -13.85 (-0.67%)
     

  • 10-Yr Bond

    4.5040
    +0.0550 (+1.24%)
     

  • NASDAQ

    16,340.87
    -5.40 (-0.03%)
     

  • VOLATILITY

    12.55
    -0.14 (-1.10%)
     

  • FTSE

    8,433.76
    +52.41 (+0.63%)
     

  • NIKKEI 225

    38,229.11
    +155.13 (+0.41%)
     

  • CAD/EUR

    0.6789
    +0.0011 (+0.16%)
     
MARKETS LIVE BLOG:

STOCKS CLIMB AS DOW POSTS 8TH STRAIGHT WIN

Fed's Michelle Bowman echoes higher-for-longer mantra for interest rates

The Zacks Analyst Blog Highlights: Cubist Pharmaceuticals, bluebird bio, Amgen, Incyte and Array

Zacks Equity Research

For Immediate Release

Chicago, IL – December 11, 2014 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include the Cubist Pharmaceuticals (CBST-Free Report), bluebird bio (BLUE-Free Report), Amgen (AMGN-Free Report), Incyte (INCY-Free Report) and Array (ARRY-Free Report).

Today, Zacks is promoting its ''Buy'' stock recommendations. Get #1Stock of the Day pick for free.

Here are highlights from Wednesday’s Analyst Blog:

Biotech Stock Roundup

It was a busy week for the biotech sector with several companies presenting data at the annual meeting of the American Society of Hematology (ASH). Meanwhile, yet another acquisition agreement was announced: Cubist Pharmaceuticals (CBST-Free Report) is set be acquired by Merck in the first quarter of 2015.

Recap of the Week’s Most Important Stories

1. Cubist’s shares shot up 35.3% on news that the company will be acquired by pharma major, Merck, in a deal valued at about $9.5 billion. The agreement marks growing interest in companies focusing on anti-infectives (Read more: Cubist Shoots Up on $9.5 Billion Buyout Offer from Merck). Although Cubist received an unfavorable ruling in its Cubicin patent litigation against Hospira, Merck said that it remains committed to the acquisition, which is slated to go through in the first quarter of 2015.

2. Several companies like Celgene (Read more: Celgene Up on Positive Revlimid Data Presented at ASH), Amgen (Read more: Amgen Unveils Positive Results from Blood Cancer Studies), ImmunoGen (Read more: ImmunoGen Reports Encouraging Data on Cancer Drug), Agios (Read more: Agios Reports Encouraging Data on Leukemia Drug) and Pharmacyclics (Read more: Pharmacyclics Presents Imbruvica Data at the ASH Meeting) among others presented data at the annual meeting of ASH.

Another company that stood out at ASH is bluebird bio (BLUE-Free Report) -- shares shot up a whopping 72.39% on encouraging early-stage data on LentiGlobin BB305 for the treatment of subjects with beta-thalassemia major and severe sickle cell disease.

3. Amgen (AMGN-Free Report) gained earlier than expected FDA approval for its leukemia drug, Blincyto. Although the label comes with a boxed warning, approval came five months ahead of schedule (Read more: Amgen's Blincyto Gets FDA Nod, Carries Boxed Warning). Amgen also successfully expanded the label of Xgeva, which can now be used for the treatment of hypercalcemia of malignancy refractory to bisphosphonate therapy (Read more: Amgen Successfully Expands Xgeva Label in the U.S.).

4. Incyte’s (INCY-Free Report) sole marketed product, Jakafi, gained approval for a rare and progressive blood cancer - polycythemia vera (PV.V) – in the U.S. This makes Jakafi the first and only FDA approved product for PV (Read more: Incyte's Jakafi Gets FDA Approval for Polycythemia Vera). The label expansion should boost Jakafi’s sales significantly. Incyte had another set of good news with the company and its partner, Eli Lilly, reporting positive late-stage results on their experimental rheumatoid arthritis treatment, baricitinib. Baricitinib is one of the most promising pipeline candidates for both Incyte and Lilly.

5. Array’s (ARRY-Free Report) shares shot up 14.3% with the company set to regain rights to its late-stage MEK inhibitor, binimetinib, from Novartis. Array stands to receive up to $85 million once the deal closes (Read more: Array BioPharma Regains Binimetinib Rights from Novartis).

Today, Zacks is promoting its ''Buy'' stock recommendations. Get #1Stock of the Day pick for free.

About Zacks Equity Research

Zacks Equity Research provides the best of quantitative and qualitative analysis to help investors know what stocks to buy and which to sell for the long-term.

Continuous coverage is provided for a universe of 1,150 publicly traded stocks. Our analysts are organized by industry which gives them keen insights to developments that affect company profits and stock performance. Recommendations and target prices are six-month time horizons.

Zacks "Profit from the Pros" e-mail newsletter provides highlights of the latest analysis from Zacks Equity Research. Subscribe to this free newsletter today.

About Zacks

Zacks.com is a property of Zacks Investment Research, Inc., which was formed in 1978. The later formation of the Zacks Rank, a proprietary stock picking system; continues to outperform the market by nearly a 3 to 1 margin. The best way to unlock the profitable stock recommendations and market insights of Zacks Investment Research is through our free daily email newsletter; Profit from the Pros. In short, it's your steady flow of Profitable ideas GUARANTEED to be worth your time! Register for your free subscription to Profit from the Pros.

Get the full Report on CBST - FREE
Get the full Report on BLUE - FREE
Get the full Report on AMGN - FREE
Get the full Report on INCY - FREE
Get the full Report on ARRY - FREE

Follow us on Twitter: http://twitter.com/zacksresearch

Join us on Facebook: http://www.facebook.com/home.php#/pages/Zacks-Investment-Research/57553657748?ref=ts

Zacks Investment Research is under common control with affiliated entities (including a broker-dealer and an investment adviser), which may engage in transactions involving the foregoing securities for the clients of such affiliates.

Media Contact
Zacks Investment Research
800-767-3771 ext. 9339
support@zacks.com
http://www.zacks.com

Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit http://www.zacks.com/performance for information about the performance numbers displayed in this press release.


Read the analyst report on CBST

Read the analyst report on BLUE

Read the analyst report on AMGN

Read the analyst report on INCY

Read the analyst report on ARRY


Zacks Investment Research